- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Cytiva is conducting gene therapy trials and received FDA approval to continue the trials.
1 report, 1 independent
Updated Aug 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cytiva is conducting gene therapy trials and received FDA approval to continue the trials.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA approval expands patient access to therapies for ACCORD.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaRocket to relaunch rare disease trial after FDA approval The US Food and Drug Administration (FDA) has given Rocket Pharmaceuticals approval to continue its pivotal Phase II trial of gene therapy RP-